Drug Database
NI
nilotinib
✓ ApprovedMolecularMD · ABL1 · Companion diagnostic
What is nilotinib?
nilotinib is a companion diagnostic developed by MolecularMD. It is approved for therapeutic indications via others.
Drug Profile
| Company | MolecularMD |
| Drug Class | Companion diagnostic |
| Molecular Target | ABL1, BCR |
| Route | Others |
| Status | Approved |
Sources: ClinicalTrials.gov, MolecularMD
Mechanism of Action
Molecular Targets
nilotinib acts on 2 molecular targets:
| ABL1 | ABL proto-oncogene 1, non-receptor tyrosine kinase (c-ABL, bcr/abl) |
| BCR | BCR activator of RhoGEF and GTPase (CML, ALL) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
nilotinib is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Uterine cancer | ✓ Approved |
Related Research Articles
Unable to load articles right now.